For patients with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CML), the use of the BCR–ABL1 tyrosine kinase inhibitor (TKI) imatinib led to 8-year overall survival (OS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback